MBX, uniQure among biotechs raising nine-figure sums: Public Equity Report

NASDAQ-traded life sciences companies raised more than $1 billion via follow-ons this week, with most of the deals driven by clinical catalysts.

The largest offering went to gene therapy developer uniQure N.V. (NASDAQ:QURE), whose treatment for Huntington’s disease showed disease-modifying effects in pivotal study results announced Wednesday morning. The news drove uniQure’s shares up 248% on Wednesday. It proposed after market hours to raise $200 million, then priced a $300 million offering ahead of Friday’s session. Leerink, Stifel, Guggenheim and Van Lanschot Kempen are underwriters...